Jefferies on Compass Pathways (CMPS): 'We are 75-85%+ confident FDA approves COMP360 for TRD depression'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $18.00 price target on Compass Pathways (NASDAQ: CMPS).The analyst comments "Big ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
